KAZIA THERAPEUTICS LTD
KAZIA THERAPEUTICS LTD (KZIA): 1 pipeline candidate · ~16 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
15.7 months
D/E 0.53 · 0% dilution
Lead: Phase 1
1 candidate
N/A
N/A
A transparent, data-derived signal for KAZIA THERAPEUTICS LTDacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$159.6M
Cash
$69.5M
Quarterly Burn
$13.3M
Runway
15.7 mo
Revenue
$42K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| evt801 | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
16
Total value held
$3.5M
| Holder | Shares | Value |
|---|---|---|
| balyasny asset management l.p. | 193,114 | $1.4M |
| flputnam investment management co | 142,469 | $1.1M |
| royal bank of canada | 34,340 | $255K |
| barclays plc | 23,999 | $179K |
| raymond james financial inc | 15,749 | $117K |
| ubs group ag | 13,934 | $104K |
| rockefeller capital management l.p. | 12,700 | $94K |
| laird norton wetherby trust company, llc | 12,400 | $92K |
| qube research & technologies ltd | 10,608 | $79K |
| osaic holdings, inc. | 8,744 | $65K |
Showing top 10 of 16 institutional holders of KAZIA THERAPEUTICS LTD. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in KAZIA THERAPEUTICS LTD's pipeline?
KAZIA THERAPEUTICS LTD (KZIA) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is KAZIA THERAPEUTICS LTD's lead drug candidate?
KAZIA THERAPEUTICS LTD's most advanced tracked candidate is evt801 (Phase 1) for Solid Tumor, Adult.
What is KAZIA THERAPEUTICS LTD's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, KAZIA THERAPEUTICS LTD has approximately 15.7 months of cash runway.
What is KAZIA THERAPEUTICS LTD's market capitalization?
KAZIA THERAPEUTICS LTD's market capitalization is approximately $159.6M.
Who is the CEO of KAZIA THERAPEUTICS LTD?
Dr. John Edwin Friend II, M.D. is the chief executive officer of KAZIA THERAPEUTICS LTD (KZIA).
Get the full picture on KAZIA THERAPEUTICS LTD
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.